Boston Technology Corporation Joins Medidata AppConnect Partner Program

Share Article

Among one of the first companies to be certified as an AppConnect Partner, BTC was selected for its digital health experience as well as its work building highly usable and scalable consumer mobile applications.

McKinley Hackett, VP - Business Development at BTC, speaking at the panel session at Medidata Symposium

McKinley Hackett, VP - Business Development at BTC, speaking at the panel session at Medidata Symposium

Our digital health expertise, coupled with Medidata’s Patient Cloud and Clinical Cloud, can help create compelling mobile health tools that add tremendous value to the field of clinical trials,” said Shyam Deval, President, Boston Technology Corporation.

Boston Technology Corporation (BTC), a Boston-based digital health technology services company has been chosen as one of the first Medidata AppConnect Program Partners. BTC creates innovative patient and provider experiences and IoT human interface mobile and web applications for provider organizations, research institutions, biotechs, medical device companies, and leading universities.

Medidata AppConnect, a software development kit (SDK) that is part of Medidata Patient Cloud®, provides the flexibility to gather and process a wide range of data from nearly any type of mobile application. AppConnect partners have the expertise to build HIPAA and FISMA-compliant mobile apps and remote patient research programs for clinical trials. These apps may collect subjective and objective data from patients that is then pulled into the regulatory-compliant and secure environment of the Medidata Clinical Cloud®.

Among one of the first companies to be certified as an AppConnect Partner, BTC was selected for its digital health experience as well as its work building highly usable and scalable consumer mobile applications.

“We are excited to collaborate with Medidata,” said Shyam Deval, President, Boston Technology Corporation. “Researchers are faced with many challenges today, including lower participation rates, selection biases and mounting costs. These are precisely the areas where we can help them leverage the power of mobility. Coupled with Medidata’s Patient Cloud and Clinical Cloud, we can create compelling mobile health tools that add tremendous value to the field of clinical trials,” he added.

“Medidata is building an ecosystem of skilled developers to help life sciences companies seamlessly bring mobile health tools into the highly structured realm of clinical development,” said Kara Dennis, Medidata’s Managing Director of mHealth. “We’re pleased that our inaugural AppConnect partners include leading digital health experts such as BTC, a company with a proven track record building secure, patient-centric mobile and web solutions for clinical research. Working together, we can provide our joint customers with the capabilities to increase the efficiency of R&D programs, improve the experience for patients and accelerate the development of new medical treatments.”

BTC recently built a Medidata AppConnect-enabled mobile app called ‘MediDate,’ which was used by participants during a simulation at the 2016 Medidata Symposium in Phoenix. The app was developed to demonstrate how mHealth tools can be used to measure motor skills such as hand dexterity, in a manner that meets the requirements of clinical studies.

At Medidata Symposium, B. McKinley Hackett III, BTC’s Vice President, Business Development participated on a panel session with other AppConnect partners to discuss trends and lessons learned in developing clinical research apps.

About Boston Technology
Boston Technology Corporation, a Boston based digital health technology services company provides mobile and web solution development for secure patient experience and engagement, medical and clinical research and IoT Human Interface applications. Visit our website for more information on applications developed by BTC for major biotech companies, universities and hospitals.

About Medidata
Medidata is reinventing global drug development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including nearly 800 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies, from study design and planning through execution, management and reporting.

Read more about the apps built by Boston Technology Corporation for major healthcare and life sciences companies here.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Suparna Rao
@BostonTechCorp
since: 03/2010
Follow >
Visit website